Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
Comparative Effects of Single Versus Twice-Daily Ramipril Dosing on Renal Function in Patients With Chronic Kidney Disease and Heart Failure With Reduced Ejection Fraction: Evaluation of Plasma Renin Activity, Malondialdehyde, Interleukin-6, Albuminuria, and Cystatin C
Evi Liliek Wulandari
80 participants
Jun 30, 2025
INTERVENTIONAL
Conditions
Summary
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.
Eligibility
Inclusion Criteria2
- Female or Male with age \>18 years old
- Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction \< 40%)
Exclusion Criteria8
- Receiving hemodialysis therapy
- History of intolerance to ACE inhibitors
- Refractory hyperkalemia
- Pregnancy
- History of angioedema to ACE inhibitors
- Receiving sacubitril-valsartan therapy
- Receiving ARB therapy
- Hypotension with blood pressure \<90/60, or patients in shock.
Interventions
Ramipril administered either as 10 mg once daily or 5 mg twice daily for 30 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07259512